Small-molecule inhibitor of ARHGAP9 and application of small-molecule inhibitor in enhancing anticancer efficacy of cells

By degrading ARHGAP9 protein with the small molecule inhibitor cyperaminin, the shortcomings of ARHGAP9 inhibitors in the prior art were solved, the anti-tumor efficacy of CAR-T and CAR-NK cells was improved, the experimental process was simplified and the cost was reduced. It significantly enhances the killing ability of a variety of cancer cells.

CN118986943AActive Publication Date: 2024-11-22THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV

Patent Information

Application Number
CN202411162055.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-22
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The lack of effective ARHGAP9 inhibitors in the prior art has led to the problems of complex operation, expensive and inefficient use of ARHGAP9 in cancer research and CAR-T/CAR-NK cell therapy, and CAR-T and CAR-NK cells. Insufficiency of anti-tumor in solid tumors.

Method used

Develop a small molecule inhibitor trophin, which can degrade the ARHGAP9 protein expressed by treating immune cells or immune-engineering cells in vitro, and improve the anti-tumor activity of cells, including adding trophin to cell culture medium or using Crispr/gRNA knockout ARHGAP9 gene.

Benefits of technology

Pyrolithin significantly improves the anti-cancer efficacy of CAR-T and CAR-NK cells, simplifies the ARHGAP9 inhibition experiment, reduces the complexity and cost of operation, and enhances the killing ability of a variety of cancer cells, especially in solid tumors and Effectiveness in hematoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986943A_ABST
    Figure CN118986943A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a small-molecule inhibitor of ARHGAP9 as well as an inhibition method and application thereof. The invention firstly provides a method for improving the antitumor activity of cells through in-vitro treatment, wherein the cells comprise immune cells and immune engineering cells; the method comprises the following steps: knocking out the ARHGAP9 gene in the cell or culturing the cell by using a small molecule drug to degrade ARHGAP9 protein expressed by the cell; the small molecular medicine comprises butenocin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a small molecule inhibitor of ARHGAP9 and its application in enhancing the anti-cancer efficacy of cells. Background Art

[0002] The Rho (RAS homolog) family is a class of Ras superfamily members that contain a GTPase domain. Their activity is regulated by their GTPase domain, switching between the inactive Rho-GDP and active Rho-GTP forms, acting as a molecular switch. Rho family proteins have complex functions and are involved in cell morphology, motility, division, gene expression, and cytoskeletal regulation. They are known to be associated with cardiovascular disease, tumor invasion and metastasis, autoimmune diseases, Parkinson's disease, and other diseases. The Rho-GAPs subfamily is an inhibitory molecule of Rho-GTP signaling, with 47 known members. ARHGAP9 (RhoGTPase activating protein 9) is one of the members of the Rho-GAPs subfamily. However, there are contradictions in the current reports on the functions of ARHGAP9 in cancer. Some articles report that ARHGAP9 is a pro-oncogene, including that ARHGAP9 can promote the proliferation and metastasis of colon cancer cells (Sun et al. Tissue cell. 2022); ARHGAP9 is highly expressed in ovarian cancer and negatively correlated with patient prognosis, and can be used as a prognostic indicator for ovarian cancer (Shen et al. Transl Cancer Res. 2021; 10: 4440-4453.). However, there are also contrary reports suggesting that ARHGAP9 is a tumor suppressor gene, including bioinformatics analysis that found that compared with patients with low ARHGAP9 expression, patients with breast cancer and bladder cancer with high ARHGAP9 expression have longer survival and better prognosis (Chen et al. Oncol Lett. 2019; 18: 6017-6025.); ARHGAP9 inhibits the proliferation and migration of liver cancer cells (Zhang et al. Cell Death Dis. 2018; 9: 916.); ARHGAP9 knockout can promote lung cancer metastasis (Song et al. Genomics. 2023). Therefore, the role of ARHGAP9 in the occurrence and development of cancer remains controversial. Currently, no ARHGAP9 inhibitors have been reported. Currently, mainstream scientific research can only use siRNA, shRNA, and Crispr / gRNA technologies to knock down or knock out ARHGAP9, but these methods have problems such as complex operation, high cost, and poor reproducibility. Therefore, the development of small molecule inhibitors that can effectively inhibit ARHGAP9 can greatly facilitate ARHGAP9 inhibition experiments in scientific research and help subsequent research.

[0003] On the other hand, in recent years, cell therapies represented by CAR-T and CAR-NK have achieved great success in clinical cancer treatment. In 2012, after experiencing two relapses of acute lymphoblastic leukemia, Emily, an American girl, became the first child with leukemia to be cured by CAR-T therapy after CAR-T treatment. Currently, there are 9 CAR-T therapies that have been put on the market for clinical use, of which 6 target CD19 and 3 target BCMA, which are used to treat B cell lymphoma and multiple myeloma respectively. Several dual-target CAR-T cell products are also in clinical trials, such as those targeting CD19 / CD20, CD19 / CD22, BCMA / CD38, BCMA / CS1, etc. (Cancers. 2023 Feb 4; 15(4): 1003.). CAR-NK is similar to CAR-T therapy. It also uses genetic engineering methods to express CAR molecules on NK cells and then injects them into the body for anti-tumor treatment. In clinical trials, the response rate reached 73%, significantly prolonging the patient's survival. Currently, CAR-NK therapy is reported to have better safety than CAR-T therapy, does not cause fatal cytokine storm and neurotoxicity, and can be prepared in advance without HLA matching (N Engl J Med. 2020 Feb 6; 382 (6): 545-553.). However, the current effects of CAR-T and CAR-NK therapy in solid tumors are poor, mainly due to the immunosuppressive microenvironment of solid tumors, which causes the infused CAR-T and CAR-NK to infiltrate solid tumors and inhibit their function in the solid tumor microenvironment. Existing clinical trials are underway to express chemokine receptors on the surface of CAR-T cells and use chemokine ligands highly expressed by solid tumors to promote the infiltration of CAR-T cells into tumor tissues (NCT03602157). Regarding CAR-T activation, a large number of reports have confirmed that the combined use of immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab can effectively enhance the anti-tumor effect of CAR-T therapy by blocking the PD-1 and CTLA-4 inhibitory receptors of CAR-T cells, or by using gene editing strategies to knock out immune checkpoint receptors such as PD1 and TIGIT in CAR-T cells (Mol Cancer. 2022 Mar 18; 21(1):78; Front Immunol. 2023 Jun 9:14:1175920.). However, there are currently no reports linking the inhibition of ARHGAP9 with the anti-tumor efficacy of CAR-T or CAR-NK. Summary of the Invention

[0004] In view of this, the purpose of the present invention is to provide a small molecule inhibitor for inhibiting ARHGAP9 in vitro and an inhibition method and its use in providing anti-cancer efficacy of immune cells and immune-engineered cells, so as to supplement the deficiencies of the existing technology. The specific technical solution is as follows.

[0005] A method for improving the anti-tumor activity of cells through in vitro treatment, wherein the cells include immune cells or immune-engineered cells; the method includes knocking out the ARHGAP9 gene in the cells or culturing the cells with small molecule drugs to degrade the ARHGAP9 protein expressed by the cells; the small molecule drugs include butegrin.

[0006] It is understood that the “small molecule inhibitor” described in the present invention specifically refers to butebase as a small molecule inhibitor of ARHGAP9.

[0007] Furthermore, the immune cells include T cells or NK cells; the immune engineering cells include CAR-T cells or CAR-NK cells.

[0008] Further, the operation of culturing the cells with butegrin includes adding butegrin to the cell culture medium; the addition ratio is 6 μM butegrin for treating 1×10 5 ~1×10 6 cells, and the culture time is 3-60 hours.

[0009] In one embodiment of the present invention, the components of the culture medium include RPMI1640, 10% FBS, 50 μM 2-mercaptoethanol, 1× sodium pyruvate, 1× non-essential amino acids, 1% penicillin / streptomycin, 25 mM HEPES, 50 U / mL mouse IL2, 5 ng / mL mouse IL-7 and 25 ng / mL IL-15.

[0010] It is understood that the above cell culture medium is a conventional cell culture medium, and the components of the above cell culture medium are only examples and not limitations. Other culture media that can culture T cells or NK cells can also be used.

[0011] Furthermore, the means of knocking out the ARHGAP9 gene in the cells includes using siRNA, shRNA or Crispr / gRNA.

[0012] In one embodiment of the present invention, the means for knocking out the ARHGAP9 gene in the cell is Crispr / gRNA; the sequence of the gRNA involved is shown in SEQ ID NO.2~4.

[0013] On the other hand, the present invention also provides the use of butea batatas in preparing an in vitro induced degradation agent for ARHGAP9 protein in immune cells or immune-engineered cells.

[0014] Furthermore, the immune cells include T cells or NK cells; the immune engineering cells include CAR-T cells or CAR-NK cells.

[0015] On the other hand, the present invention also provides an anti-tumor reagent, which includes immune-engineered cells and butegrin; the immune-engineered cells include CAR-T cells or CAR-NK cells; the butegrin is configured as an in vitro immune activator of the immune-engineered cells, used to induce the degradation of ARHGAP9 protein expressed by the immune-engineered cells in vitro.

[0016] Furthermore, the butegrin and immune-engineered cells in the anti-tumor agent are independently prepared according to unit doses, and the ratio of butegrin to immune-engineered cells is 6 μM butegrin for treating 1×10 5 ~1×10 6 immune-engineered cells.

[0017] Furthermore, the anti-tumor agent is applicable to tumor types including solid tumors and hematological tumors.

[0018] Furthermore, the tumor targets suitable for the anti-tumor agent include CD19, BCMA, CD20, CD22, EGFRvIII, CD123, CD33, HER2, CD38, CD70, PSMA, B7-H3, GPC3, GCC, Claudin18.2, CEA, CD5, EpCAM, GD2 and / or Mesothelin, etc.

[0019] It is understandable that the above targets are common solid tumor or hematological tumor targets, and the experiments in the examples of the present invention have demonstrated that the immune cells and immune-engineered cells treated with butebase are effective against a variety of solid tumors and hematological tumors.

[0020] Beneficial technical effects

[0021] The present invention provides a method for improving the anti-cancer efficacy of immune cells or immune-engineered cells by knocking out the ARHGAP9 gene of immune cells or immune-engineered cells or inducing degradation of ARHGAP9 protein expressed by immune cells or immune-engineered cells in vitro.

[0022] In the preliminary experiments of the present invention, after a large number of screenings, it was found that the small molecule inhibitor Butebase can effectively induce the degradation of ARHGAP9 protein of CAR-T cells or CAR-NK cells in vitro, thereby significantly improving the anti-cancer efficacy of CAR-T cells or CAR-NK cells in various cancer cells. The experiment found that only a low concentration of Butebase is needed to achieve the above technical objectives, which greatly avoids the problems of complex operation, high cost, low knockout efficiency, and poor reproducibility of traditional siRNA, shRNA, and Crispr / gRNA technologies for knocking down or knocking out ARHGAP9 in T and NK cells, and has a broader clinical application prospect.

[0023] In summary, the present invention proposes that butegrin can be used as a new small molecule inhibitor of ARHGAP9, which has dual uses in scientific research and clinical practice. In scientific research, butegrin can be used to conveniently inhibit ARHGAP9 from activating NK cells and CD8 + T cells, for NK and CD8 + T cell activation experimental research. In terms of clinical applications, CAR-T and CAR-NK cells can be pretreated with butegrin before infusion, or butegrin can be administered after infusion of CAR-T and CAR-NK cells to enhance the anti-tumor effect of CAR-T and CAR-NK. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] To more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be derived from these drawings without inventive effort.

[0025] Figure 1 In vitro co-culture experiments confirmed that knockout of ARHGAP9 could activate NK and CD8 + T cell killing cancer cell activity;

[0026] Figure 2 Conditional knockout mice confirmed that ARHGAP9 knockout can activate tumor-infiltrating NK and CD8 + T cell anticancer activity;

[0027] Figure 3 To verify that butegrin can inhibit the expression of ARHGAP9 in gradient concentration and gradient time, and activate NK and T cells to release cytokines;

[0028] Figure 4 To verify that butegrin treatment can effectively enhance the anti-tumor effects of CAR-T and CAR-NK cell therapy. DETAILED DESCRIPTION

[0029] To make the purpose, technical solutions, and advantages of the embodiments of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0030] As used herein, "and / or" includes any and all combinations of one or more of the associated listed items.

[0031] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.

[0032] It should be noted that, in this document, the terms "comprises," "includes," or any other variations thereof are intended to encompass non-exclusive inclusion, such that a process, method, article, or apparatus comprising a series of elements includes not only those elements but also other elements not explicitly listed, or elements inherent to such process, method, article, or apparatus. In the absence of further limitations, an element defined by the phrase "comprising a ..." does not exclude the presence of other identical elements in the process, method, article, or apparatus comprising the element.

[0033] As used in this specification, the term "about" typically means that the value + / -5%, more typically the value + / -4%, more typically the values + / -3%, more typically the value + / -2%, or even more typically + / -1%, or even more typically + / -0.5%.

[0034] In this specification, some embodiments may be disclosed in a format of being within a certain range. It should be understood that such description of "being within a certain range" is only for convenience and brevity and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of a range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values ​​within this range. For example, the range The description of should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within this range, for example, 1, 2, 3, 4, 5, and 6. The above rules apply regardless of the breadth of the range.

[0035] Specific drawings:

[0036] Figure 1 AB is a Western blot analysis of ARHGAP9 expression in NK92MI cells knocked out by Crispr / gRNA method; Figure 1 C shows the co-culture of control or AHRGAP9 knockout NK92MI cells with different tumor cells at different concentrations, and the cell lysis rate was detected by calcein; Figure 1 D is the flow cytometry analysis of cytokine expression in NK92MI cells of the control group or AHRGAP9 knockout group; Figure 1 E is the effect of knocking out AHRGAP9 on the mRNA expression of cytokines expressed by NK92MI detected by qPCR; Figure 1 F: Primary NK cells from WT or ARHGAP9 knockout mice co-cultured with different tumor cells; Figure 1 G is primary CD8 derived from WT or ARHGAP9 knockout OT-I mice + T cells were co-cultured with different tumor cells.

[0037] Figure 2 A is the strategy for constructing ARHGAP9 conditional knockout mice; Figure 2 B is the genotype identification of ARHGAP9 conditional knockout mice; Figure 2 CD is the anti-leukemia E.G7 cell transplant tumor and colon cancer MC38 cell transplant tumor effect of ARHGAP9 conditional knockout mice; Figure 2 E is the flow cytometry detection of cytokine release by tumor-infiltrating NK cells in transplanted tumors; Figure 2 F is the flow cytometry detection of cytokine release by tumor-infiltrating T cells in transplanted tumors.

[0038] Figure 3 A is a schematic diagram of the ARHGAP9 inhibitor screening strategy; Figure 3 B is the Western blot detection result of butea batin-induced degradation of ARHGAP9-HA fusion protein; Figure 3 CD are the Western blot results of the changes in the overall expression of ARHGAP9 protein induced by butebase in Jurkat and NK92MI cells; Figure 3 EF is qPCR detection of changes in the ability of butea batatas to induce cytokine expression in Jurkat and NK92MI cells.

[0039] Figure 4 AB represents butea baterin treatment that enhances the anti-tumor growth effect of CAR-T cells against colon cancer MC38-hCD19 cell transplants; Figure 4CD shows that butegrin treatment enhances the anti-tumor growth effect of CAR-NK cells against human B lymphoblastoma Daudi cell transplants.

[0040] Example 1

[0041] In vitro knockout of ARHGAP9 was used to verify its effect on NK cell and T cell killing of tumor cells.

[0042] (1) First, ARHGAP9 was knocked out in NK cells in vitro. The control group used one Crispr / gRNA plasmid to package lentivirus, and the knockout group used three Crispr / gRNA plasmids to package lentivirus. NK92MI cells (NK cells from patients with malignant non-Hodgkin's lymphoma) were infected to construct an ARHGAP9 knockout cell line. Three monoclonal clones were selected from the control group and six monoclonal clones were selected from the treatment group. Western blot was used to verify the knockout effect. The results showed that the ARHGAP9 knockout cell line of NK92MI was successfully constructed. Monoclonal cells including three control clones (Con gRNA1-1, Con gRNA1-2, Con gRNA1-3), gARH#1-3, gARH#2-4, and gARH#3-3 were used for subsequent experiments ( Figure 1 AB). The gRNA information involved in this example is shown in Table 1.

[0043] Table 1 NO. Abbreviation sequence 1 Con gRNA GAACCCCTGATTGTATCCGCA 2 gARH#1 GTTGTTTCATGGTTCCCTGG 3 gARH#2 GGCCTGAGACAACTCCTCCA 4 gARH#3 CCATGAAACAACTTCGGCCC

[0044] (2) Calcein-AM was used to stain acute leukemia cells (THP1, U937, Molm-13, Mono-Mac-6), large B-cell lymphoma cells (DB), non-small cell lung cancer cells (NCI-H1299), prostate cancer (DU-145), ovarian cancer (OVCAR3), breast cancer cells (MCF-7), and melanoma cells (Colo-858). The above cells were co-cultured with the constructed ARHGAP9 knockout NK92MI cells. Among them, the ARHGAP9 knockout NK92MI cells were effector cells (E) and the tumor cells were target cells (T).

[0045] (3) Detecting the calcein fluorescence released into the culture medium after target cell death can reflect the death of target cells.

[0046] The results showed that ARHGAP9 knockout could significantly increase the killing effect of NK92MI cells on cancer target cells, with a good dose-effect relationship ( Figure 1C), that is, as the effector-target ratio increases, the lysis rate of tumor cells also increases. Flow cytometry analysis further confirmed that ARHGAP9 knockout can increase the expression of NK cell activation markers (including TNFα, IFNγ, GZMB, and Perforin) ( Figure 1 D). qPCR detection of mRNA expression of NK cell activation markers also confirmed that ARHGAP9 knockout significantly increased the release of cytokines by NK92MI cells, including TNFα, IFNγ, GZMB, and Perforin ( Figure 1 E).

[0047] Furthermore, this example used NK cells isolated from the spleen of WT and ARHGAP9 knockout experimental animals (ARH- / -NK) to co-culture with various mouse tumor cell lines in vitro, including leukemia cell lines Yac-1 and C1498, and colon cancer cell line MC38. It was also confirmed that ARHGAP9 knockout can effectively increase the killing effect of NK cells on various tumor cells ( Figure 1 F) In addition, this example also isolated OT-I CD8 T cells from the spleens of wild-type OT-I mice and ARHGAP9 knockout OT-I mice. + T cells (which can specifically recognize target cells expressing chicken ovalbumin OVA antigen) were co-cultured with a variety of tumor cells expressing OVA at a gradient concentration, including the leukemia cell line E.G7-OVA, the melanoma cell line B16F10-OVA, and the colon cancer cell line MC38-OVA. It was also confirmed that ARHGAP9 knockout could significantly increase OT-I CD8 + T cells kill tumor cells Figure 1 G).

[0048] Example 2

[0049] Conditional knockout mice confirmed that ARHGAP9 knockout can activate NK cells and T cells to release cytokines, inhibit the growth of transplanted tumors, and prolong the survival of mice.

[0050] To further verify whether ARHGAP9 has immunosuppressive effects, this example constructed fl / fl Mice were bred with NCR1-Cre and CD4-Cre mice to obtain offspring NK cell conditional knockout ARHGAP9 mice (ARHGAP9 fl / fl NCR1-Cre) and T cell conditional knockout ARHGAP9 mice (ARHGAP9 fl / fl CD4-Cre). Knockout mouse construction strategy is as follows ( Figure 2 As shown in A), the knockout mice were successfully constructed by genotyping verification ( Figure 2 B).

[0051] Then the experiment used ARHGAP9 + / + NCR1-Cre mice and ARHGAP9 + / + CD4-Cre mice were used as negative controls. Mice were subcutaneously inoculated with colon cancer cells MC38 and leukemia cells E.G7. The volume of transplanted tumors was recorded every other day, and the survival time of mice was also recorded. The results showed that conditional knockout of ARHGAP9 in NK or T cells could significantly inhibit the growth of transplanted tumors and prolong the survival time of mice ( Figure 2 CD), as can be seen in the figure, tumor size decreases over time and the survival rate of mice increases. It is worth noting that the method used in this example to record the changes in mouse tumor size after inoculation with leukemia cells E.G7 is in line with technical operating standards in this field.

[0052] Furthermore, the infiltrating lymphocytes in the transplanted tumor tissue were separated by Percoll separation, and NK and CD8 + T cell and immune activation markers. The results showed that ARHGAP9 knockout in NK cells significantly increased the proportion of tumor-infiltrating NK cells expressing IFNγ, TNFα, and GZMB ( Figure 2 E). At the same time, ARHGAP9 can also increase tumor infiltrating CD8 + T and CD4 + T cells express IFNγ, TNFα ( Figure 2 F).

[0053] In summary, the results of this example can confirm that ARHGAP9 is an immunosuppressive molecule. Knockout of ARHGAP9 can activate NK and T cells to release cytokines and enhance the anti-tumor immune efficacy of immune cells.

[0054] Example 3

[0055] The above examples have confirmed that knocking out ARHGAP9 in animal models in vitro and in vivo can effectively activate NK and CD8 + The anti-tumor effect of T cells on tumor cells suggests that inhibiting ARHGAP9 expression can effectively enhance the anti-tumor effects of CAR-T and CAR-NK cells. However, the use of siRNA, shRNA, and Crispr / gRNA technologies to knock down or ablate ARHGAP9 in T and NK cells is complex, expensive, inefficient, and poorly reproducible, limiting their clinical application. Therefore, the development of effective small molecule inhibitors could significantly address the technical challenges and reduce costs in the preparation of these CAR-T and CAR-NK cells.

[0056] The research team of the present invention targeted ARHGAP9 and constructed an EGFP fluorescent plasmid driven by the ARHGAP9 promoter sequence and an HA expression plasmid fused with the ARH coding region sequence. After packaging the lentiviruses, the plasmids were infected with Jurkat cells. After obtaining a stable expression cell line, the team conducted large-scale small molecule drug screening on the FDA-approved compound library and the natural product compound library. Figure 3 A), a variety of small molecule drugs in these compound libraries were co-incubated with infected Jurkat cells. It was found that Butein can effectively induce the degradation of ARHGAP9 fusion HA protein expressed by the plasmid (the present invention constructs an ARHGAP9-HA fusion expression plasmid and uses anti-HA antibodies for detection to avoid detecting endogenous ARHGAP9 protein in the cell. Therefore, when HA expression is found to be reduced, it can be confirmed that the expressed ARHGAP9-HA fusion protein is degraded.) It has a good time-effect and dose-effect relationship ( Figure 3 B).

[0057] Jurkat and NK92MI cells were treated with butein at different concentrations (2.5 μM, 5 μM, 10 μM, 20 μM) for 24 h, and with butein at 20 μM for different time periods (3 h, 6 h, 12 h, 24 h, 48 h). Western blot analysis with anti-ARHGAP9 antibody confirmed that Butein could inhibit the expression of ARHGAP9 in a time- and dose-dependent manner. Figure 3 CD). Therefore, the experiments in this example fully confirmed that butegrin, as a small molecule inhibitor, can effectively induce the degradation of ARHGAP9.

[0058] The information of butea batatasin is shown in Table 2.

[0059] Table 2

[0060] The present invention further verifies the effect of butea batatasin as an inhibitor of ARHGAP9 on NK and T cell activation.

[0061] Jurkat and NK92MI cells were treated with gradient concentrations of butebase (0μM, 5μM, 10μM, 20μM) in vitro. The specific method was to add gradient concentrations of butebase to the corresponding cell culture medium to culture the cells, and qPCR was used to detect the expression of cytokines after culture. The results showed that butebase could effectively promote the expression of cytokines IFNγ, TNFα, and GZMB in Jurkat and NK92MI cells, showing a good dose-effect relationship ( Figure 3 EF), that is, the more butea superba added, the higher the expression of cytokines.

[0062] In summary, the results of this example demonstrate that butegrin can induce the degradation of ARHGAP9, thereby promoting the activation of NK and T cells.

[0063] Example 4

[0064] This example provides an evaluation of butea superba as a small molecule inhibitor of ARHGAP9 induced degradation to enhance the anti-tumor effect of CAR-T and CAR-NK cell therapy. The specific steps are as follows.

[0065] (1) Day 1: 293FT cells were plated. The healing rate was about 70% on the second day. The culture medium was DMEM. + 10% FBS + 1% BSA.

[0066] (2) Day 2: Co-transfect hCD19-CAR-GFP plasmid and viral capsid plasmid. The plasmid ratio is shown in Table 3. Carefully replace the 293FT cell culture medium, add 10 mL of fresh culture medium, add the liposome and plasmid mixture dropwise to the culture plate, and return to the incubator for 48 h.

[0067] Table 3

[0068] (3) Day 3: Add CD8 + T cells were added to each well at 1 × 10 5 Cells were cultured overnight for subsequent titer detection.

[0069] (4) Day 4: Collect the virus. Disinfect the ultracentrifuge tube cap, sleeve, and ultracentrifuge tube with 70% ethanol. Wash the ultracentrifuge tube twice with PBS to remove residual ethanol, dry it, and disinfect it under UV for 30 minutes. Collect the viral supernatant with a syringe and filter it into an ultracentrifuge tube using a 0.45μm filter membrane. Add 8ml of lentiviral culture medium to the cells and incubate for 24 hours for secondary virus collection. Pipette 2.5mL of 10% sucrose concentrate (100mM NaCl, 0.5mM EDTA 2Na2H2O, 10% sucrose, 50mM Tris-HCl (pH7.4)) and carefully add it to the bottom of the centrifuge tube. Place the balance in a biosafety cabinet, add sterile PBS to ensure that the weight difference between the 6 tubes is less than 0.1g, insert the sleeve, and tighten the lid. Then centrifuge at 10000g and 4℃ for 4 hours. Unscrew the lid in a biosafety cabinet, take out the centrifuge tube with tweezers, pour out all the supernatant, evaporate for 3 minutes, resuspend the virus in 200 μL sterile PBS (without calcium and magnesium), and divide into 50 μL portions and freeze at -80°C.

[0070] (5) Leave a small amount of virus, take 10 μL and add it to 90 μL PBS, mix well, take another 10 μL and add it to 90 μL PBS, dilute 10 times in sequence (1, 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 The diluted virus was added to the cultured CD8 + T was added to a 96-well plate, and 4 μL of infection enhancement reagent TransGA (Gene Gene) was added to each well and cultured overnight for the determination of virus titer.

[0071] (6) Day 5: Take out the 96-well plate and count the number of GFP-positive cells under a microscope. Calculate the virus titer based on the virus dilution multiple. -4 If there is one positive GFP cell in the well, the virus titer is: 1 / 10 -4 =1×10 4 TU / μL=1×10 7 TU / ml.

[0072] (7) Infect target cells: Isolate CD8 T cells from the spleen of transgenic mice expressing Cas9 + T cells, the operation method is based on EasySep Mouse CD8 + Isolated T cells were stimulated with CD3 / CD38 antibodies in vitro for 2 days using the T Cell Isolation Kit (Stem Cell #19853). The culture medium consisted of RPMI-1640, 10% FBS, 50 μM 2-mercaptoethanol, 1× sodium pyruvate, 1× non-essential amino acids, 1% penicillin / streptomycin, 25 mM HEPES, 50 U / mL mouse IL-2, 5 ng / mL mouse IL-7, and 25 ng / mL IL-15.

[0073] (8) Day 6: Add 50 μg / mL RetroNectin (recombinant human fibronectin, Takara, T100A) to a 6-well plate and coat the plate overnight.

[0074] (9) Day 7: Remove the RetroNectin and add the lentivirus to the plate at an MOI of 10 based on the measured viral titer. Incubate for 6 hours. Discard the supernatant and wash the plate once with PBS. + T cells were collected by centrifugation at 1200 rpm for 5 min and 1×10 5Cells / well were added to a 6-well plate (3 mL culture system), and the infection was enhanced by centrifugation at 3200 rpm for 2 h at 32°C, followed by further culture for 3 days.

[0075] (10) Day 8: 20 μM / L Butegra (6 μM: 1×10 6 The cells were treated with PBS as the control group for 2 days.

[0076] (11) Day 10: Collect cells by centrifugation, select GFP-positive cells by flow cytometry, and count them according to 3×10 6 The cells were transferred via the tail vein to mice that had been subcutaneously inoculated with colon cancer MC38-hCD19 cells (tumor inoculation 5 days in advance). Subsequently, the growth of the transplanted tumors was monitored every other day and the survival time of the mice was recorded. The transplanted tumor volume was >2000mm 3 Set as ethical death endpoint.

[0077] Experimental results: The results of CAR-T cell therapy showed that CAR-T cells treated with Butebase had a stronger ability to kill tumor cells, significantly inhibited the growth of transplanted tumors, and prolonged the survival of mice ( Figure 4 AB).

[0078] Example 6

[0079] Similar to the CAR-T experimental protocol in Example 5, Cas9-expressing NK92MI cells were further constructed as CAR-NK source cells. The cell culture conditions were: Alpha-MEM supplemented with 10% FBS, 0.1 mM 2-mercaptoethanol, 1% penicillin / streptomycin, 0.2 mM inositol, and 0.02 mM folic acid.

[0080] (1) The RetroNectin-coated plate infection method was also used. Lentivirus was added to the plate at an MOI of 10 and incubated for 6 hours. The supernatant was discarded and the plate was washed once with PBS. The cultured NK cells were collected after centrifugation at 1200 rpm for 5 minutes and then plated at a concentration of 1×10 5 Cells / well were added to a 6-well plate (3 mL culture system), centrifuged at 3200 rpm and 32°C for 2 h to enhance infection, and then cultured for another 3 days.

[0081] (2) Day 8: Add 20 μM / L Butegra (e.g. 6 μM: 1×10 6 The cells were treated with PBS as the control group for 2 days.

[0082] (3) Day 10: Collect cells by centrifugation, and select GFP-positive CAR-NK cells by flow cytometry. 6The cells were adopted into mice bearing tumors that had been subcutaneously inoculated with human B-lymphoblastoma Daudi cells (7 days before the tumor was inoculated) via the tail vein. CAR-NK cells were adopted every 3 days for a total of 4 times. The growth of the transplanted tumors was monitored every other day, and the survival time of the mice was recorded. The transplanted tumor volume was >2000mm 3 Set as ethical death endpoint.

[0083] Experimental results: The results of CAR-NK cell therapy showed that CAR-NK cells treated with Butebase had a stronger ability to kill tumor cells, significantly inhibited the growth of transplanted tumors, and prolonged the survival of mice ( Figure 4 CD).

[0084] In summary, the results of Examples 5-6 showed that butegrin, as a small molecule inhibitor of induced degradation of ARHGAP9, can effectively enhance the anti-tumor effect of CAR-T and CAR-NK cell therapy.

[0085] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are protected by the present invention.

Claims

1. A method for improving the anti-tumor activity of cells by in vitro treatment, characterized in that: The cells include immune cells or immune engineering cells; the method includes knocking out the ARHGAP9 gene in the cells or using small molecule drugs to culture the cells to degrade the ARHGAP9 protein expressed by the cells; the small molecule drugs include butenatin.

2. The method according to claim 1, characterized in that The immune cells include T cells or NK cells; the immune engineering cells include CAR-T cells or CAR-NK cells.

3. The method according to claim 1, characterized in that The operation of culturing the cells with butegrin includes adding butegrin to the cell culture medium; the addition ratio is 6 μM butegrin for treating 1×10 5 ~1×10 6 The culture time is 3-60 hours.

4. The method according to claim 1, characterized in that The means for knocking out the ARHGAP9 gene in the cells include using siRNA, shRNA or Crispr / gRNA.

5. Application of butea superba in the preparation of in vitro induced degradation agent of ARHGAP9 protein in immune cells or immune engineering cells.

6. The use according to claim 5, characterized in that The immune cells include T cells or NK cells; the immune engineering cells include CAR-T cells or CAR-NK cells.

7. An anti-tumor agent, characterized in that: The anti-tumor agent includes immune-engineered cells and butenatin; the immune-engineered cells include CAR-T cells or CAR-NK cells; the butenatin is configured as an in vitro immune activator of the immune-engineered cells, and is used to induce in vitro degradation of ARHGAP9 protein expressed by the immune-engineered cells.

8. The anti-tumor agent according to claim 7, characterized in that In the anti-tumor agent, butea superba and immune engineering cells are independently prepared according to unit doses, and the ratio of butea superba to immune engineering cells is 6 μM butea superba for treating 1×10 5 ~1×10 6 Immunoengineered cells.

9. The anti-tumor agent according to claim 7, characterized in that The anti-tumor agents are applicable to tumor types including solid tumors and hematological tumors.

10. The anti-tumor agent according to claim 7, wherein the tumor targets applicable to the anti-tumor agent include CD19, BCMA, CD20, CD22, EGFRvIII, CD123, CD33, HER2, CD38, CD70, PSMA, B7-H3, GPC3, GCC, Claudin18.2, CEA, CD5, EpCAM, GD2 and / or Mesothelin.

Citation Information

Patent Citations

  • Application of butein in preparing the medicine for preventing the blood vessel from regenerating

    CN101336909A

  • Human liver cancer marker and application thereof

    CN110878355A

  • Method for screening of immunological tolerance associated disease gene RGS1 based on immunological tolerance dendritic cell

    CN1840707A

  • Methods and compositions relating to the treatment of cancer

    US20150374692A1

  • Use of WW protein domain for inhibiting activation of map kinases

    WO2007113689A2

Cited By

  • Construction method of ARHGAP9 gene knockout cell and application of ARHGAP9 gene knockout cell in tumor resistance

    CN119020420A

  • A method for constructing ARHGAP9 gene knockout cells and its application in anti-tumor

    CN119020420B

  • 5-phenoxy tetrazole compound, reagent thereof, preparation method of 5-phenoxy tetrazole compound and application of 5-phenoxy tetrazole compound in preparation of antitumor drugs

    CN120441500A

  • A 5-phenoxytetrazolyl compound, its reagent, preparation method and application in the preparation of antitumor drugs

    CN120441500B

  • A 5-phenoxytetrazole compound, combination therapy, and its application in antitumor treatment

    GB2704785A